Alzheimer's disease drug development pipeline: 2026. [PDF]
Cummings JL +6 more
europepmc +1 more source
Artificial intelligence‐assisted nanozyme design for medical and environmental applications
AI‐assisted nanozyme design integrates cross‐source data and machine learning to enable predictive structure‐activity relationships, accelerating intelligent diagnostics, precision therapeutics, and environmental surveillance. Abstract Nanozymes, a class of nanomaterials with intrinsic enzyme‐like catalytic activities, have emerged as promising ...
Xiaolin Guo +7 more
wiley +1 more source
Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors: Biology and Therapeutic Opportunities. [PDF]
Tralongo P +11 more
europepmc +1 more source
Molecular theranostics: principles, challenges and controversies
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley +1 more source
Metabolic Reprogramming and Neurotransmitter Signaling Co-Option in the Glioma Immune Microenvironment: Dual-Axis Regulation of Immunosuppression. [PDF]
Zhao P +4 more
europepmc +1 more source
Abstract Neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease are characterized by progressive neuronal loss driven by oxidative stress and inflammation. Quercetin, a dietary flavonoid with established antioxidant and anti‐inflammatory properties, has emerged as a potential neuroprotective agent.
In Ho Cho +6 more
wiley +1 more source
Translational progress and bottlenecks in neurotransmitter-cancer research [2000-2025]: an integrated bibliometric and interventional trial analysis. [PDF]
Zhang M +5 more
europepmc +1 more source
Pregabalin Efficacy in Treatment of Chronic Neurogenic Cough
The use of neuromodulators for chronic cough has increased; however, the choice of medication, dosing regimen, and duration are still unclear. This longitudinal study of 95 adults taking pregabalin, 75 mg twice daily, for CNC demonstrated 78% improvement or resolution of cough, 17% unchanged, 1% worse cough, with a mean of 6 weeks of therapy, and only ...
Jacqui Allen +3 more
wiley +1 more source
Advances in pharmacotherapy for vascular cognitive impairment and vascular dementia: An update of 2025. [PDF]
Tran DK, Kuan YC, Huang LK, Hu CJ.
europepmc +1 more source
Optical neuromodulation with IR light allows stimulation of the PNS without the need for physical contact with the target nerve or without requiring any genetic modification. The clinical translation of this technique will pave the way to the development of neural interfaces for restoring sensory feedback in individuals with limb amputation.
Federica Piccirillo +20 more
wiley +1 more source

